The availability of clotting factor concentrates of both factor VIII and factor IX have improved hemophilia treatment to a great extent. Many more improvements like physiotherapy, and comprehensive care are needed to give better care. One important complication that occurs, but is often set aside is the development of inhibitors. When an inhibitor develops in a patient of severe hemophilia then the care becomes more difficult and expensive. Eradication of the inhibitor is possible by Immune tolerance induction (ITI), this paper explains some important essential factors and practical issues during my experience with ITI.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–443
Witmer C, Young G (2013) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4(1):59–72
Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P et al (2014) The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients. Indian J Hematol blood Transfus 30(4):356–363
Kar A, Phadnis S, Dharmarajan S, Nakade J (2014) Epidemiology & social costs of haemophilia in India. Indian J Med Res 140:19–31
Ghosh K, Ghosh K (2016) Management of Haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 32(3):347–355
Saxena K (2013) Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 4:49–56
Colowick AB, Bohn RL, Avorn J, Ewenstein BM (2000) Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 96(5):1698–1702
Rocha P, Carvalho M, Lopes M, Araújo F (2015) Costs and utilization of treatment in patients with hemophilia. BMC Health Serv Res 15:484. https://doi.org/10.1186/s12913-015-1134-3
Elisa Mancuso M, Cannavo A (2015) Immune tolerance induction in hemophilia. Clin Investig 5:321–335
Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL, Reiss UM (2015) US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 21:559–567
Miller CH (2018) Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review. Haemophilia 24(2):186–197
Adcock DM, Favaloro EJ (2015) Pearls and pitfalls in factor inhibitor assays. Int Jnl Lab Hem 37(1):52–60
Kempton CL, Meeks SL (2014) Toward optimal therapy for inhibitors in hemophilia. Hematol Am Soc Hematol Educ Program 2014:364–371
Valentino LA, Allen G, Gill JC, Hurlet A, Konkle BA, Leissinger CA et al (2013) Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 19(3):e151–e166
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G et al (2017) Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 377(9):809–818
Sherman A, Biswas M, Herzog RW (2017) Innovative approaches for immune tolerance to factor VIII in the treatment of Hemophilia A. Front Immunol 8:1604. https://doi.org/10.3389/fimmu.2017.01604
Mauz-Korholz C, Korholz D, Gobel U (1997) Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Thromb Haemost 78:959
Mauser-Bunschoten EP, Karel Nieuwenhuis H, Roosendaal G, Marijke van den Berg G (1995) Low-dose immune tolerance induction in Hemophilia A patients with inhibitors. Blood 86(3):983–988
Kavakli UK, Baytan B, Kazanci E, Sayli TY, Oren H, Celkan T, Gurse T (2008) Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors. Haemophilia 14:315–322
Berntorp E, Astermark J, Carlborg E (2000) Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica 85(10):48–50
Hay CRM, DiMichele DM (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119(6):1335–1344
Malec LM, Journeycake J, Ragni MV (2016) Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia 22(6):e552–e554
Brackmann H-H, White GC 2nd, Berntorp E, Andersen T, Escuriola-Ettingshausen C (2018) Immune tolerance induction: what have we learned over time? Haemophilia 24(3):3–14
Escuriola Ettingshausen C, Kreuz W (2013) The immune tolerance induction (ITI) dose debate: does the International ITI study provide a clearer picture? Haemophilia 19(1):12–17
Minno GD (2014) Predictors of ITI success according to evidence from literature data. Haemophilia 20(6):27–43
Jimenez-Yuste V, Oldenburg J, Rangarajan S, Peiro-Jordan R, Santagostino E (2016) Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study. Haemophilia 22(6):859–865
Barnes C, Brown SA, Curtin J, Dunkley S (2014) When is enough… enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors. Haemophilia 20:e275–e279
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Seth, T. Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India. Indian J Hematol Blood Transfus 36, 458–463 (2020). https://doi.org/10.1007/s12288-019-01218-2
- Eradication of inhibitors
- Inherited hemophilia